CONTEXT: Dr. Dushyant Sahani, director of CT at Massachusetts General Hospital in Boston, evaluated the effects of the anti-angiogenic drug bevacizumab (Avastin, Genentech) on patients with advanced hepatocellular carcinoma (HCC). Perfusion CT was used compare changes in tumor perfusion with tumor size and biomarkers such as alpha-fetoprotein (AFP) and circulating endothelial cells (CEC).
CONTEXT: Dr. Dushyant Sahani, director of CT at Massachusetts General Hospital in Boston, evaluated the effects of the anti-angiogenic drug bevacizumab (Avastin, Genentech) on patients with advanced hepatocellular carcinoma (HCC). Perfusion CT was used compare changes in tumor perfusion with tumor size and biomarkers such as alpha-fetoprotein (AFP) and circulating endothelial cells (CEC).
RESULTS: Perfusion CT was performed on 17 patients with HCC before receiving Avastin and again 12 days following treatment. Sahani performed a dynamic first-pass perfusion exam using 16-slice CT after administering 70 mL of iodinated contrast agent. Within two weeks of therapy, blood flow, blood volume, and permeability of surface area products all decreased, while mean transit time increased markedly. Magnitude of change was greater in responders, although almost all the tumors showed some alterations in perfusion CT. No correlation was found between the change in tumor perfusion and AFP, CEC, and tumor size. Treatment effects captured on perfusion CT are probably at the molecular level and therefore too early to manifest with any alterations in tumor size, a criterion currently used for estimating tumor response, according to Sahani.
IMAGE: Elevated blood flow (A) and blood volume (B) depicted with CT perfusion correlate with an HCC liver lesion that appears in a contrast-enhanced CT (C).
IMPLICATIONS: The research demonstrates perfusion CT is an effective method for evaluating early therapeutic results of Avastin on HCC. The study also shows that tumor response may not be determined at this early stage by more traditional diagnostic factors such as tumor size, AFP, and CEC.
"We would next like to test this method with other novel anticancer drugs that have anti-angiogenic effects," Sahani said.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.